Amgen reported robust financial performance with strong revenue and EPS growth, bolstered by positive outcomes from Repatha which could enhance payer support and market acceptance in the short term. Despite uncertainties from patent litigation and increased competition from biosimilars, management's optimistic guidance and strategic initiatives are likely to sustain investor confidence. Overall, the stock is expected to experience a positive impact in the next 1â€“2 weeks.

[1]